Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
The arylsulfonamide derivatives described herein were such potent inhibitors of human immunodeficiency virus type 1 (HIV-1) protease (enzyme, E) that values for the inhibition constants (K(i)) could not be determined by conventional steady-state kinetic techniques (i.e., the minimal enzyme concentration usable for the activity assay was much greater than the value of the dissociation constant). Consequently, two alternative methods were developed for estimation of K(i) values. The first method employed kinetic determinations of values for k(1) and k(-1), from which K(i) was determined (k(-1)/k(1)). The second method was a competitive displacement assay used to determine binding affinities of other inhibitors relative to that of GW0385. In these assays, the inhibitor of unknown affinity was used to displace [(3)H]GW0385 from E.[(3)H]GW0385. From the concentration of E.[(3)H]GW0385 at equilibrium, the concentrations of enzyme-bound and free inhibitors were calculated, and the ratio of the K(i) value of the unknown to that of GW0385 was determined (K(i,unknown)/K(i,GW0385)). The values of k(1) were calculated from data in which changes in the intrinsic protein fluorescence of the enzyme associated with inhibitor binding were directly or indirectly monitored. In the case of saquinavir, the fluorescence changes associated with complex formation were large enough to monitor directly. The value of k(1) for saquinavir was 62 +/- 2 microM(-1) s(-1). In the case of GW0385, the fluorescence changes associated with complex formation were too small to monitor directly. Consequently, the value of k(1) was estimated from a competition experiment in which the effect of GW0385 on the binding of E to saquinavir was determined. The value of k(1) for GW0385 was estimated from these experiments to be 137 +/- 4 microM(-1) s(-1). Because E.[(3)H]GW0385 was stable in the standard buffer at room temperature for greater than 33 days, the value of the first-order rate constant for dissociation of E.[(3)H]GW0385 (k(-1)) could be estimated from the time-course for exchange of E.[(3)H]GW0385 with excess unlabeled GW0385. The value of k(-1) calculated from these data was (2.1 +/- 0.1) x10(-6) s(-1) (t(1/2) = 91 h). The K(i) value of wild-type HIV-1 protease for GW0385, calculated from these values for k(1) and k(-1), was 15 +/- 1 fM. Three multidrug resistant enzymes had K(i) values for GW0385 that were less than 5 pM.
Hanlon
Mary H
MH
GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Upper Merion, Pennsylvania 19405, USA.
Porter
David J T
DJ
Furfine
Eric S
ES
Spaltenstein
Andrew
A
Carter
H Luke
HL
Danger
Dana
D
Shu
Arthur Y L
AY
Kaldor
Istvan W
IW
Miller
John F
JF
Samano
Vicente A
VA
D019943:Amino Acid Substitution / Q000235:genetics; D001667:Binding, Competitive / Q000235:genetics; D002219:Carbamates; D002846:Chromatography, Affinity; D002850:Chromatography, Gel; D003911:Dextrans / Q000737:chemistry; D019281:Dimerization; D005663:Furans; D016333:HIV Protease / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006868:Hydrolysis; D007700:Kinetics; D011485:Protein Binding / Q000235:genetics; D019258:Saquinavir / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D013050:Spectrometry, Fluorescence; D013379:Substrate Specificity; D013449:Sulfonamides / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology
D002219:Carbamates; D003911:Dextrans; D005663:Furans; C494906:GW0385; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; C025614:sephadex; D016333:HIV Protease; D019258:Saquinavir